GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Molecular Dx Has Your (Copy) Number
CNV Detection and Analysis Tools Are Being Used To Fill Genetic Diagnostic Gaps
Significant progress is being made toward the development of an effective HIV-AIDS vaccine. In autumn 2009, a collaborative effort between the Ministry of Health in Thailand, the U.S. Military, and the U.S. National Institute of Allergy and Infectious Disease announced the first encouraging results from an efficacy trial—31% prevention of infection in a 16,402-person community-based trial in Thailand. With this encouraging news in the background, several companies are working toward an AIDS vaccine. So, when do you think one will be approved in the U.S.?